The primary therapeutic role of Семпрекс (Acrivastine) is commonly used to help with symptomatic relief across the major areas affected by allergic responses, and generally supports patients during difficult episodes by easing distress. The medication is applied in scenarios where additional management of discomfort is required and assists with maintaining functional stability.

---

Key Areas of Symptom Management

Семпрекс is commonly applied in conditions characterized by periods of heightened symptoms, including seasonal and perennial allergic rhinitis (hay fever), various forms of urticaria (hives), allergic dermatitis, and localized reactions to insect bites. It is relevant for easing challenging symptoms that interfere with daily functioning, such as frequent sneezing, profuse runny nose, itchy eyes, and allergic pruritus related to inflammatory or irritative states.

“The supportive relief Семпрекс contributes helps patients cope more steadily with symptom fluctuations, supporting general well-being during symptomatic phases.”

In clinical settings, Семпрекс is applied during phases when symptoms become more noticeable, contributing to easing the overall symptom load during episodes of heightened discomfort.

Quick Fact: Used for managing Pruritus and Dermal Discomfort

---

Management of Acute and Chronic Symptoms

The medication is useful in situations involving certain distressing symptoms related to both acute and chronic allergic triggers. For instance, it plays a role in managing symptoms that may become intense or disruptive in acute allergic flares (like sudden hives) or is used in situations involving recurrent or episodic manifestations, such as throughout a specific pollen season. Семпрекс assists with maintaining functional stability by providing supportive relief when symptoms interfere with routine activities.

The eligibility for using Acrivastine (Семпрекс) is defined strictly by regulatory labeling, which establishes populations that are allowed, restricted, or prohibited from use.

Category	Official Regulatory Eligibility Status
Approved Age Group	Adults and adolescents 12 years of age and older. Use is not established and not recommended for children under 12. The single-entity product is not recommended for adults over 65 due to insufficient study data.
Absolute Contraindications	Use is prohibited for individuals with known hypersensitivity to acrivastine or related antihistamines. It is also contraindicated for patients with severe hypertension, severe coronary artery disease, or those taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.
Organ Function & Physiological States	The medicine is contraindicated in patients with severe renal impairment (e.g., creatinine clearance le 48 mL/min). Use is not recommended during pregnancy or lactation due to a lack of adequate human safety data.
Use Restrictions	Caution is required for patients with hepatic impairment and those with pre-existing conditions like diabetes mellitus, hyperthyroidism, or conditions that may lead to urinary retention.

Regulatory documentation defines who can and cannot use the medicine by establishing absolute prohibitions based on conditions such as severe cardiovascular disease and MAOI use, while restricting use based on age, kidney function, and pregnancy status.

The official regulatory documents for Семпрекс (Acrivastine) detail specific pharmacokinetic and pharmacodynamic interactions that dictate its co-administration profile.

Category	Interacting Substances	Regulatory-Documented Outcome
Exposure-Modifying Agents	Ketoconazole, Erythromycin, Cimetidine	Co-administration results in a pharmacokinetic interaction pattern that formally increases the plasma concentration (AUC) of Acrivastine.
Additive Central Depressants	Alcohol, other CNS Depressants	Documented to produce additive pharmacodynamic effects, specifically increased central nervous system depression.

Interaction Restrictions and Conditions

A primary interaction restriction applies when the product is the fixed-dose combination containing pseudoephedrine. This combination is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), mandating a 14-day separation rule after cessation of MAOI therapy before administration. For the Acrivastine component, the official labeling notes that its systemic exposure is not meaningfully affected by food intake, and therefore no food restrictions are imposed. Regulatory documents also specify that the combination product is not recommended in the presence of severe renal impairment, due to the potential for component accumulation and altered clearance.

How Семпрекс Works

This mechanism operates through dual modulation of two distinct physiological regulatory systems.

Peripheral H1 Receptor Blockade and Anti-Inflammatory Cascade Modulation

The antihistaminic component acts as a highly selective Inverse Agonist at peripheral Histamine H1 receptors, preventing the binding of endogenous histamine and stabilizing the receptor in an inactive state. This molecular interaction disrupts the initial inflammatory cascade, which physiologially attenuates the signaling that leads to increased capillary permeability and excitation of sensory nerve endings.

---

Local alpha1-Adrenergic Activation and Vascular Tone Regulation

The decongestant component acts as both a direct alpha1-Adrenergic Agonist and an indirect sympathomimetic, promoting the release of Norepinephrine ( NE) to stimulate local alpha1-receptors in the nasal lining. This results in local induction of vasoconstriction of the microvasculature, thereby results in reduced blood volume within the mucosal microcirculation.

---

Mechanistic Complementarity and Physiological Profile

These two distinct mechanisms operate in parallel: the H1 blockade dampens the inflammatory mediator activity, while the alpha1 agonism actively promotes local vascular smooth muscle contraction. This complementary approach modulates the physiological consequence of histamine-driven fluid leakage and targets the physiological process of vascular engorgement.

How to Use Семпрекс: Official Administration Guidelines

Семпрекс, containing the active ingredient Acrivastine, is a preparation administered strictly via the oral route as a hard gelatin capsule. The product is frequently encountered as a fixed-dose combination with a decongestant, which defines its specific administration protocol.

The standardized adult dosing regimen for this capsule requires the intake of one unit per dose. Administration should be spaced out at intervals of every 4 to 6 hours as required, with a strict limitation that the total daily intake must not exceed four doses within a 24-hour period.

Specific Administration Conditions

Parameter	Official Instruction
Intake Timing	May be taken with or without food.
Duration Pattern	Use is generally short-term or episodic; continuous efficacy beyond 14 days is not established.
Dose Compliance	The prescribed dose must not be exceeded.

Rules for Special Populations and Missed Doses

The use of Семпрекс is officially restricted to adolescents 12 years of age and older, as safety and efficacy have not been established for younger children. A constraint on use involves renal function: the medicine is not recommended for administration to patients with moderate to severe renal impairment (creatinine clearance ≤ 48 mL/min) due to altered elimination of the components.

In the event of a missed dose, the standard instruction is to take the dose as soon as it is remembered. However, if the time is near for the next scheduled dose, the missed dose must be skipped. Patients must be explicitly instructed not to double the dose. This structured administration ensures adherence to the established protocol.

Research Evidence / Overview of Studies for Семпрекс (Apremilast)

---

Evidence for use in Plaque Psoriasis

Research for plaque psoriasis was evaluated in large, short-term Randomized, Placebo-Controlled Trials (RCTs) across multiple centers, followed by long-term open-label extension phases. These studies primarily focused on adults with chronic plaque psoriasis classified as moderate to severe. Researchers examined specific, standardized measurements such as the Psoriasis Area and Severity Index (PASI) and the Static Physician Global Assessment (sPGA), which are used in research exploring how symptoms change over time. Studies monitored the frequency with which pre-determined measurement thresholds (such as PASI-75) were met, reporting patterns observed in the study groups and the placebo groups. Analysis of long-term follow-up studies, which was observed in participants for up to five years, described how these measurement levels evolved in the observed populations who continued the regimen.

Evidence for use in Psoriatic Arthritis

Семпрекс was studied for active psoriatic arthritis primarily in large, multi-center, short-term randomized trials. These studies were conducted during periods of increased symptom activity and evaluated adults with active disease. The research examined outcomes related to systemic or functional imbalance by monitoring measurements such as the American College of Rheumatology (ACR) response criteria and the Health Assessment Questionnaire–Disability Index (HAQ-DI). Studies monitored the frequency with which these thresholds were met, reporting patterns observed in the study groups and the placebo groups.

What is Still Uncertain About Семпрекс Evidence

The research contributes to the broader evidence landscape but has several known limitations. Comparative evidence is lacking in studies that directly compare this regimen to all other available treatments within the same trial structure. The long-term effects are not fully established beyond the intermediate follow-up periods (around five years). Additionally, evidence quality varies across studies, particularly for non-pivotal trials and smaller observational cohorts. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from the ESTEEM 1 phase III study
2. PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (Phase III Trial)
3. Apremilast for oral ulcers in patients with Behçet’s syndrome: RELIEF trial findings

Common questions about Семпрекс (FAQ)

---

Q: Is Семпрекс a non-drowsy medication, or does it cause significant sleepiness?

Official product information lists drowsiness, known as somnolence, as a very common side effect. Because of this, regulatory guidance advises caution when operating heavy machinery or driving.

Q: How quickly should I expect to feel the decongestant effects of Семпрекс?

Семпрекс is officially characterized by a rapid onset of action for allergy symptoms. However, the specific time to feel the maximum decongestant effect is not detailed in the official product information.

Q: Why does the drug Cемпрекс sometimes difficult to find or listed as discontinued in some regions?

In certain regions, such as the United States, the brand name combination product containing acrivastine and pseudoephedrine has been discontinued by the original manufacturer. This decision was generally for business reasons and was not due to safety concerns.

Q: Is Семпрекс safe for children, and if so, at what age?

The product is indicated for use in adults and adolescents who are 12 years of age and older. Safety and effectiveness have not been established for use in children younger than 12 years.

Q: Can taking Семпрекс cause trouble falling asleep, and is there a recommended time to take the last dose?

Difficulty sleeping (insomnia) and nervousness are listed as common side effects of the medication. The regulatory documents provide a dosing interval and a strict 24-hour limit which must be followed.

Q: Can Семпрекс be taken with or without food?

Official administration instructions state that the medicine may be taken with or without food. This is because official documents indicate that food intake does not significantly change how the body absorbs the antihistamine component.

Q: What is Семпрекс primarily prescribed for, besides general allergies?

The combination product is primarily indicated for the temporary relief of symptoms associated with seasonal allergic rhinitis, commonly known as hay fever. It is also used to relieve symptoms associated with other upper respiratory conditions such as the common cold and sinusitis.

Q: Can Семпрекс be used for symptoms of the common cold, or only for allergies?

Official sources confirm that this combination of an antihistamine and decongestant is used to temporarily relieve symptoms caused by the common cold, as well as those from allergies or other breathing illnesses. It works by addressing congestion, a runny nose, and sneezing.

Q: Is there a maximum number of days or weeks that Семпрекс is safe to take continuously?

Regulatory labeling states that the medicine is intended for short-term or episodic use. The label indicates that continuous effectiveness beyond 14 days has not been established. If symptoms persist beyond seven days, regulatory guidance suggests consulting with a healthcare professional.

Q: Are there any dietary restrictions, like grapefruit juice, that apply to Семпрекс?

While the medicine can be taken with or without food, regulatory guidance in some regions advises caution with grapefruit juice while taking acrivastine. This is because the juice could potentially increase the likelihood of experiencing side effects.

Q: Will Семпрекс help with a cough or sore throat related to post-nasal drip?

The medicine works to relieve nasal symptoms like congestion and runny nose, which can contribute to post-nasal drip. While relief of cough is not its primary labeled use, the reduction of these core nasal symptoms may help reduce associated irritation.

Q: Can Семпрекс affect my ability to concentrate or operate machinery?

Official warnings state that this medicine may cause some people to become dizzy, drowsy, or less alert. Regulatory guidance recommends exercising caution when driving a motor vehicle or operating machinery.

Q: Can Семпрекс cause changes in heart rate or rhythm?

The pseudoephedrine component is associated with potential cardiovascular effects. Adverse reactions can include changes in heart rhythm, such as palpitations or tachycardia (a fast heart rate). The product is strictly contraindicated for individuals with severe coronary artery disease.

Q: What is the effect of urine pH on the elimination of the pseudoephedrine in Семпрекс?

Pharmacokinetic data in regulatory documents indicate that the body's elimination of pseudoephedrine is susceptible to changes in urinary pH. The component is cleared from the body at a faster rate when the urine is more acidic.

Q: Is there a generic version of the combination drug Семпрекс-D available?

Yes, although the original brand-name combination product may be discontinued in some areas, generic versions containing the same active ingredients (acrivastine/pseudoephedrine) have been available.

Q: Will Семпрекс help with nasal congestion that is not caused by allergies?

The decongestant component works by narrowing blood vessels to reduce swelling in the nasal lining. For this reason, it may provide relief for nasal congestion caused by conditions other than allergies, such as the common cold.

Q: Is it possible for Семпрекс to cause anxiety or nervousness?

Yes, nervousness is listed in official documents as a common side effect of the medicine. Feelings of anxiety or excitability have also been reported, particularly with the use of the decongestant component.

Q: Can taking Cемпрекс make me feel lightheaded or dizzy when standing up quickly?

Dizziness is listed as a common side effect of the medicine. Though not specifically labeled as such, lightheadedness or dizziness when changing positions is a common experience with medications that cause general dizziness.

Q: Are there any documented cases of addiction or misuse associated with the decongestant in Семпрекс?

The decongestant component, pseudoephedrine, is monitored by regulatory agencies due to its potential use in the illicit manufacture of methamphetamine. Federal and local regulations place restrictions on the sale and purchase amounts of products containing this ingredient.

Q: Does Семпрекс contain any ingredients that might be a concern for people with lactose intolerance?

Some product formulations of the combination drug may contain lactose monohydrate as an inactive ingredient. Individuals with hereditary problems of galactose intolerance or lactose deficiency should be aware of this excipient.

Q: Can Семпрекс be safely used by patients with mild asthma?

The medicine is not formally contraindicated for patients with asthma. Related studies have sometimes included individuals with mild, concomitant asthma, but the final assessment of use is made by a healthcare professional.

Q: Why is Семпрекс often recommended for seasonal allergic rhinitis specifically?

The medicine is indicated for seasonal allergic rhinitis because its dual action effectively treats the full range of acute symptoms. This includes the itching and sneezing caused by histamine, as well as the vascular engorgement that leads to nasal congestion.

Q: What is the typical time frame for clinical trials used to establish the efficacy of Cемпрекс?

Clinical trials for this class of medicine often use a short-term design, typically lasting a few weeks, to measure the acute relief of allergic symptoms. These are sometimes followed by longer, open-label extension phases for extended observation.

Q: Can using Семпрекс potentially affect the results of an allergy skin test?

Yes, as an antihistamine, the acrivastine component can suppress the histamine response needed for skin prick testing. Regulatory guidance suggests discontinuing the medicine for a specific period before a skin test, as it may interfere with the results.

Q: Can Семпрекс cause stomach upset or nausea?

Yes, official safety information lists nausea as a common adverse reaction of the medicine.

Q: What is the recommended storage temperature for Семпрекс capsules?

The medicine should be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F). To protect the product's stability, it must be kept away from excessive heat, moisture, and direct light.

How to Store and Dispose of Семпрекс (Acrivastine)

Official regulatory documents define the required conditions for storing and handling Семпрекс (Acrivastine) to ensure product stability and safety.

Storage Requirements

Condition	Requirement (Based on Regulatory Labeling)
Temperature Range	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not store above 30 C (86 F).
Packaging	Keep the medicine in its original package.
Child Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired medicinal product or waste material must be conducted in accordance with local requirements for pharmaceutical waste.